Time filter

Source Type

Palladino C.,University of Lisbon | Palladino C.,Hospital General Universitario Gregorio Maranon | Gomez M.L.N.,Hospital General Universitario Gregorio Maranon | Soler-Palacin P.,Autonomous University of Barcelona | And 13 more authors.
AIDS | Year: 2015

Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs. © Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved.

Loading Hospital Universitario Germans Trias i Pujol Badalona collaborators
Loading Hospital Universitario Germans Trias i Pujol Badalona collaborators